The CDC reports that the JN.1 subvariant is now responsible for about 20% of new COVID-19 cases in the US. This strain, originating from BA.2.86, is growing rapidly, especially in the Northeast. JN.1, a descendant of BA.2.86, has undergone significant mutations in its spike proteins. Initially, there were concerns it might evade vaccine protection, but such fears have not materialized.
Despite its slow initial growth, JN.1 is now gaining momentum. It has one key spike protein change from BA.2.86, making it more transmissible. The prevalence of JN.1 in the US more than doubled from late November to mid-December. Holiday travel and waning immunity are contributing to its spread.
Dr. Shishi Luo of Helix notes a sharp rise in JN.1 cases post-Thanksgiving. The WHO has labeled JN.1 a variant of interest due to its rapid spread. Dr. T. Ryan Gregory, an evolutionary biologist, predicts JN.1 will soon dominate globally.
Research indicates a slight decrease in antibody neutralization against JN.1. This could lead to a new wave of infections. European countries and others are witnessing exponential JN.1 growth and rising hospitalizations. In the US, waning immunity and low vaccination uptake are exacerbating the situation.
The latest developments highlight the need for continued vigilance and vaccination against COVID-19.
Follow the latest news on Google News
